Tokyo, Apr 3, 2006 (JCN) - Asahi Kasei Pharma Corporation and Eisai Co., Ltd. announced on March 31 that AKP and Eisai China Inc., a subsidiary of Eisai, signed an agreement on March 28 giving Eisai China exclusive rights to promote injectable formulations of AKP’s vasodilator Eril (fasudil hydrochloride) in China.
